![]() |
|
|
BEHAVIORAL PHARMACOLOGY
Laboratory of Neuropsychopharmacology (D.A.G., M.J.O., K.H.S., C.B.N.) and Laboratory of Stress Neurobiology (K.V.T.), Department of Psychiatry and Behavioral Sciences, Emory University of School of Medicine, Atlanta, Georgia
Corticotropin-releasing factor (CRF) is the major physiological regulator
of the hypothalamic-pituitary-adrenal (HPA) axis and serves to coordinate the
mammalian endocrine, autonomic, and behavioral responses to stress.
Considerable literature from clinical and preclinical data suggests that
hypersecretion of hypothalamic and/or extrahypothalamic CRF systems is a major
factor in the pathogenesis of affective and anxiety disorders. Based on this
premise, a CRF1 receptor antagonist has been hypothesized to
possess anxiolytic and/or antidepressant properties. In this study, an acute
dose of the lipophilic CRF1 receptor antagonist
3-[6-(dimethylamino)-4-methyl-pyrid-3-yl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimidin-7-amine
(R12191
Address correspondence to: Dr. Michael J. Owens, Department of
Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1639
Pierce Dr., Suite 4000 WMRB, Atlanta, GA 30322. E-mail:
mowens{at}emory.edu
This article has been cited by other articles:
Received August 6, 2002;
accepted October 8, 2002.
![]()
![]()

![]()
![]()
![]()
Y. Chen, R. A. Bender, K. L. Brunson, J. K. Pomper, D. E. Grigoriadis, W. Wurst, and T. Z. Baram
Modulation of dendritic differentiation by corticotropin-releasing factor in the developing hippocampus
PNAS,
November 2, 2004;
101(44):
15782 - 15787.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()